目的 探讨UGT1A1*28基因多态性与CPT-11治疗晚期NSCLC的毒副反应与疗效的关系.方法 外周血检测2015年6月至2016年6月在九江市第一人民医院所收治的50例晚期NSCLC患者UGTIA1*28 TATA盒基因序列,并对所有50例患者接受CPT-11为基础化疗方案的患者出现的不良反应和近期疗效随访记录,比较不同基因型之间的差别.结果 50例晚期NSCLC患者中UGTIA1*28位点突变型可以增加发生3级以上腹泻(P=0.007)和3级以上血小板减少(41.7% VS 10.5%, P=0.027)的风险.结论 在CPT-11化疗的患者中,UGTlAl*28 基因型TA6/7,或TA7/7基因型可增加晚期NSCLC患者发生Ⅲ度以上腹泻及血小板减少的风险,然而不影响化疗的近期疗效.
The Association of UGT1A1*28 Polymorphism with the Efficacy and Toxicity of Irinotecan Chemotherapy in Non-small Cell Lung Cancer
Objective To explore the realtionship UGT1A1*28 gene polymorphisms and irinotecan-associated toxicity and efficacy in treatment of non-small cell lung cancer.Methods The frequency of UGT1A1*28 TATA box thymine-adenine(TA) was performed by direct sequencing.The influence of the UGT1A1 *28 polymorphism on the short-term efficacy and toxicity of irinotecan was record.Results Among 50 patients with non-small lung cancer,marked increases in diarrhea (58.3% VS 15.8%,P=0.007) and thrombocytopenia (41.7% VS 10.5%,P=0.027) were observed in patients who had the TA6/7 or T7/7 genotype.Conclusion This study demonstated that UGT1A1*28 polymorphism TA6/7 or T7/7 increased the risk the developing grade Ⅲ or more sever diarrhea and thrombocytopenia for patients after receiving irinotean treatment but no influence on short-term efficacy of chemotherapy.
NETL
NSTL
万方数据
维普
